Check for updates

OPEN ACCESS

EDITED BY Songlin He, Chongqing Medical University, China

REVIEWED BY Zorica Momcilo Zivkovic, University Hospital Center Dr Dragiša Mišović, Serbia Tianyuan Yu, Beijing University of Chinese Medicine, China Taipin Guo, Yunnan University of Traditional Chinese Medicine, China

*CORRESPONDENCE Yanguo Wang tjwangyanguo@163.com Mingchi Luo luomc0909@163.com

[†]These authors have contributed equally to this work and share first authorship

SPECIALTY SECTION

This article was submitted to Children and Health, a section of the journal Frontiers in Pediatrics

RECEIVED 13 September 2022 ACCEPTED 17 October 2022 PUBLISHED 14 November 2022

CITATION

Fu S, Li Y, Li R, Ren F, Piao Y, Wang Y and Luo M (2022) Pediatric tuina for allergic rhinitis in children: A systematic review and meta-analysis of randomized controlled trials. Front. Pediatr. 10:1043322. doi: 10.3389/fped.2022.1043322

COPYRIGHT

© 2022 Fu, Li, Li, Ren, Piao, Wang and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Pediatric tuina for allergic rhinitis in children: A systematic review and meta-analysis of randomized controlled trials

Shifang Fu^{1†}, Yuetong Li^{1†}, Rongrong Li¹, Fengjiao Ren¹, Yinjing Piao², Yanguo Wang^{1*} and Mingchi Luo^{1*}

¹Department of Massage and Rehabilitation, Second Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China, ²Department of Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China

Aim: To evaluate the clinical efficacy of pediatric tuina for allergic rhinitis treatment in children.

Methods: Three English, four Chinese, one Japanese, and two Korean databases were searched for relevant literature published till February 2021, and eligible randomized controlled trials (RCTs) were included for analysis. Data were screened and extracted independently using predesigned forms. The methodological quality evaluation was performed using the tool of Cochrane bias risk assessment, and meta-analysis was performed through Review Manager 5.3.

Results: A total of 12 RCTs, which included 716 children, were selected for meta-analysis. Compared with Chinese herbal medicine, acupuncture, Western medicine, and other therapies, pediatric tuina alone or in combination with other treatments had a higher clinical effectiveness (relative risk = 1.16, 95% confidence interval [CI] = 1.08-1.25) in treating children with allergic rhinitis. Pediatric tuina also effectively improved the following signs and symptoms of allergic rhinitis in children: nasal congestion (mean difference [MD] = -0.44, 95% CI = -0.70 to -0.19), runny nose (MD = -0.39, 95% CI = -0.55 to -0.23), sneezing (MD = -0.23, 95% CI = -0.38 to -0.08), and turbinate swelling (MD = -0.26, 95% CI = -0.48 to -0.04); all differences were statistically significant.

Conclusions: The present study provided favorable evidence for the treatment of allergic rhinitis in children with pediatric tuina. However, owing to the impact of research quality, this evidence needs to be validated *via* strictly designed clinical trials.

KEYWORDS

pediatric tuina, allergic rhinitis, children, randomized controlled trials, meta-analysis

Introduction

Allergic rhinitis (AR) is a noninfectious inflammatory disease mediated by immunoglobulin (Ig) E and the most common chronic disease in children (1). Children with AR exhibit several symptoms, including sneezing, watery rhinorrhea, nasal congestion, and itching (2). The International Research Organization for Childhood Asthma and Allergy systematically assessed the prevalence of allergic

diseases in 98 countries, and the results revealed that the overall prevalence of AR in children aged 6-7 and 13-14 years was 8.6% and 14.6%, respectively (3, 4). AR not only has a negative impact on the physical and mental health, quality of life, and learning ability of children but may also lead to potential complications such as sinusitis, otitis media, and asthma (5, 6). In addition, children with AR may place a heavy burden on the family and society (7). Western medicines for the treatment of children with AR primarily comprise oral antihistamines, intranasal corticosteroids, decongestants, and leukotriene receptor antagonists (8-10). Owing to their poor compliance and obvious side effects (11, 12), some parents attempt to find other alternative therapies to relieve the symptoms of children with AR. Nondrug therapies, particularly pediatric tuina, have become a feasible strategy for the treatment of children with AR because of the advantages of safety, low cost, and easy acceptance by children (13, 14).

Pediatric tuina is an external treatment method guided by the basic principles of traditional Chinese medicine. According to the physiological and pathological characteristics of children, various techniques, such as pushing, pinching, and pressing, are used on the specific parts of a child's body to prevent and treat pediatric diseases (15, 16). Pediatric tuina has been shown to be beneficial for many diseases of infants and children, including the growth problems of preterm infants, painful conditions, musculoskeletal system disorders, psychological problems, neurological conditions, and chronic allergic diseases (such as asthma) (17-24). Several clinical trials have been published in support of the aggressive treatment of AR in children with tuina intervention; however, there is a lack of clear evidence to definitively recommend tuina as a therapeutic option. Therefore, Chinese, English, Korean, and Japanese literature databases were extensively searched for latest published RCTs to systematically evaluate the therapeutic effect of pediatric tuina alone or in combination with other therapies on children with AR with a view to improve clinical practice and further provide evidence for its use.

Methods

This study has been registered on PROSPERO (CRD 42020220029) and can be accessed at https://www.crd.york.ac. uk/PROSPERO/.

Inclusion and exclusion criteria

Only randomized controlled trial (RCT) studies were included for meta-analysis. The target study group was children and adolescents aged between 1 and 18 years who had been diagnosed with AR according to established diagnostic criteria. The treatment group received pediatric tuina alone or in combination with other therapies, including acupuncture, Chinese herbal medicine, Chinese patent medicine, and Western medicine. The control group received therapies other than pediatric tuina. Children who received another type of pediatric tuina were excluded. The results included either of the following: effective rate, nasal symptom or sign (nasal congestion, itchy nose, runny nose, sneezing, turbinate swelling, and nasal mucosal swelling) improvement scores, and total nasal symptom scores.

Reviews, meetings abstracts, case reports, comments, and duplicate papers were excluded from the meta-analysis.

Literature search and study selection

Three English databases (PubMed, Embase, and Cochrane Library), four Chinese databases (Wan Fang Database, China National Knowledge Infrastructure, the Chinese Biomedical Literature Database, and VIP Database for Chinese Technical Periodicals), one Japanese database (cinii), and two Korean databases (Korea citation index, Korean medical database) were searched for relevant literature using the following timeline: from the inception of the coverage of those databases to February 2021. For the English databases, the query strategy comprised three components: clinical condition (allergic rhinitis OR hayfever OR pollinosis), intervention (pediatric tuina OR massage OR manipulation OR manual OR acupressure OR stretching OR touch OR maneuver OR anmo OR chiropractic), and participants (children OR infants OR adolescents OR pediatrics OR toddlers OR preschoolers). For the Chinese, Korean, and Japanese databases, equivalent group terms were queried.

Data extraction and risk of bias

Two authors (LYT and LRR) independently extracted the data and performed cross-checking. Disagreements, if any, were resolved through discussion. In the event when a consensus could not be reached, the opinion of a third reviewer (WYG) was sought. For each included study, the following clinical features were extracted: 1. study characteristics (title, author, year of publication, country, and sample size); 2. participants (gender, age, and course of disease); 3. interventions; 4. course of treatment; and 5. outcome measurements, which included the nasal symptom or sign score (nasal congestion, runny nose, nasal itching, sneezing, turbinate swelling, and nasal mucosal swelling), total scores for nasal symptoms, and effective rate. To assess the quality of the included studies, two authors (LYT and LRR) independently assessed each study



using the Cochrane Collaboration tool for RCTs. Disagreements, if any, between the two reviewers were resolved through discussion and consultation with a third reviewer (WYG), if necessary. In brief, the following seven items of bias were assessed: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other deviations. Each domain was rated as being at a low risk, high risk, or unclear risk of

bias. Information was retrieved directly from the published articles and supplementary materials and by contacting the study authors when needed.

Data analysis

The meta-analysis of RCTs with available data was performed using Cochrane Collaboration's Review Manager

Study	Sample size (M/F)	ie (M/F)	Age (year)	year)	Course (month)	month)	Interventions		Outcome	Total
	Treatment	Control	Treatment	Control	Treatment	Control	Treatment	Control	MICASUIC	Durauon
Sun 2018, (25)	30 (16/14)	30 (18/12)	5.1 ± 0.6	4.9 ± 0.7	23.5 ± 11.1	$20. \pm 9.1$	Pediatric tuina	Montelukast	0.2345	3 months
Dai 2020, (26)	28 (15/13)	28 (14/14)	5.7 ± 2.2	5.5 ± 1.9	I	I	Pediatric tuina	Montelukast	Θ	1 months
Jiang 2017, (27)	30 (18/12)	30 (16/14)	3-5years, 10 5-8years, 14 8-10years, 6	3–5years, 12 5–8years, 11 8–10years, 7	23.5 ± 11.1	20.9 ± 9.1	Pediatric tuina	Loratadine + Mometasone Furoate Aqueous Nasal Spray	0245	20 days
Sun 2019, (28)	30 (14/16)	30 (13/17)	3-5years, 10 5-8years, 9 8-10years, 11	3-5y, 11 5-8y, 11 8-10y, 8	24.6±8.3	22.6 ± 7.0	Pediatric tuina	Montelukast	02345	3 months
Fu 2015, (29)	20 (13/7)	20 (12/8)	2.5-6	3-6	5.5-36	6-36	Pediatric tuina	Acupuncture	Θ	1 months
Xu 2018, (30)	30 (17/13)	30 (20/10)	6.24 ± 1.20	6.3 ± 1.3	25.8 ± 12.3	23.7 ± 13.6	Pediatric tuina + Chinese herbal pieces	Chinese herbal pieces	03	2 weeks
Chen 2016, (31)	30 (17/13)	30 (20/10)	6.24 ± 1.20	6.3 ± 1.3	25.2 ± 11.7	24.8 ± 13.5	Pediatric tuina + Chinese herbal pieces	Chinese herbal pieces	Θ	2 weeks
Xu 2009, (32)	40 (20/20)	40 (22/18)	4–10year, 37 >10year, 3	4–10years, 37 >10year, 3	12-24 m,23 24-48 m,13 >48 m,4	12-24 m,20 24-48 m,14 >48 m,6	Pediatric tuina + Chinese herbal pieces	Chinese herbal pieces	0	80 days
Shen 2015, (33)	20	20	4.3 ± 1.8	4.9 ± 1.4	23.7 ± 12.9	23.8 ± 14.1	Pediatric tuina + Chinese herbal pieces	Chinese herbal pieces	1234	2 weeks
Liu 2014, (34)	60 (34/26)		1.42–7years		4-36		Pediatric tuina + Chinese herbal pieces	Chinese herbal pieces	Θ	3 months
Fan 2019, (35)	40 (21/19)	40 (20/20)	10.02 ± 1.64	10.8 ± 1.7	$36.1 \pm 14.$	35.2 ± 14.9	Pediatric tuina + Shuangbai Granules		03	18 days
Mou 2014, (36)	30 (13/17)	30 (15/15)	2–6years, 5 6–12years, 13 12–18years, 12	2–6years: 6 6–12years, 13 12–18years, 9	I	I	Pediatric tuina + Tongqiao Biyan Tablet	Tongqiao Biyan Tablet	0	4 weeks

Fu et al.

04



5.3. For dichotomous outcomes, the effect size was analyzed via relative risk (RR) with 95% confidence intervals (CI). Continuous variable data are expressed as mean difference (MD) with 95% CI. Heterogeneity among the results of the included studies was tested using the chi-square test and combined with I² to quantitatively judge the degree of heterogeneity. $I^2 < 50\%$ and P > 0.05 indicated that the test results were not statistically heterogeneous, and the fixedeffects model was used for meta-analysis. By contrast, $I^2 >$ 50% and P < 0.1 indicated statistical heterogeneity among the results of the studies, and the random-effects model was used for meta-analysis. P < 0.05 indicated statistical significance. If the test results had a medium or high degree of heterogeneity, the source of the heterogeneity was analyzed and solutions such as subgroup analysis or sensitivity analysis were adopted. When the source could not be identified, only descriptive analysis without merging was performed.

Results

Study characteristics and risk of bias

A total of 316 potential studies were initially identified, of which 132 duplicate studies were excluded and the remaining 184 articles were further evaluated for specific relevance to the meta-analysis. After further excluding 153 articles deemed irrelevant, 31 articles remained. These 31 articles included 19 studies with incorrect data and inconsistent intervention measures, which were excluded by critically reading the original papers. Finally, a total of 12 studies (25–36), which included 716 children, were included in the meta-analysis. The literature-screening process is shown in Figure 1.

Table 1 summarizes the detailed information of the 12 included studies. These articles were published between 2009 and 2020, and six were published after 2017. Among the 12 included RCTs, 5 (41.67%) studies used pediatric tuina alone to treat AR and 7 (58.33%) used pediatric tuina in combination with herbal medicine (5 articles) and Chinese patent medicine (2 articles) for treatment.

Figures 2, 3 show an overview of the risk of bias. All studies were randomized: six were randomized using the random number table method and the other six mentioned the use of randomization but did not describe it in detail. Owing to the particularity of pediatric tuina treatment, it is impossible to implement the blinded method for children and tuina experts. Therefore, "blinding of participants and personnel" was deemed "high risk of bias" and "blinding of outcome assessment" was considered "low risk of bias." Three studies described the dropout data. None of the studies mentioned allocation hiding and selective reporting. Overall, the level of evidence was moderate.

Outcome evaluation

Effective rate

The 12 studies, which included 358 children who received pediatric tuina treatment and 358 children who did not receive tuina in the control group, focused on effective rate as the outcome index. Because of the small heterogeneity of the included studies ($I^2 = 33\%$), a fixed-effect model was used for meta-analysis. The results showed that compared with the control group, pediatric tuina had a higher clinical effectiveness (RR = 1.16, 95% CI:1.08–1.25, P < 0.01). Subsequently, a subgroup analysis of five studies using



pediatric tuina alone and seven studies using pediatric tuina combined with other treatments was performed. The results revealed that compared with the control group, the effective rate of both pediatric tuina alone (RR = 1.13, 95% CI = 1.02–1.25, P < 0.05) or combined with other therapies (RR = 1.19, 95% CI = 1.08–1.31, P < 0.05) was superior (**Figure 4**).

Nasal symptom evaluation

Nasal symptoms included nasal congestion, itchy nose, sneezing, and runny nose. Six articles evaluated the four symptoms separately, three of which were with pediatric tuina alone and three with pediatric tuina combined with other treatments. A total of 180 children who received pediatric tuina and 180 controls were included in the meta-analysis of the four symptoms of nasal congestion (Figure 5), nasal itching (Figure 6), runny nose (Figure 7), and sneezing (Figure 8). The results revealed that both pediatric tuina alone or combined with other therapies significantly improved nasal congestion (MD = -0.44, 95% CI = -0.70 to -0.19, P < 0.01), runny nose (MD = -0.39, 95% CI = -0.55 to -0.23, P < 0.01), and sneezing (MD = -0.23, 95% CI = -0.38 to -0.08, P < 0.01) but not nasal itching (P = 0.68). The results of the aggregated data showed that the heterogeneity of pediatric tuina treatment for nasal congestion and nasal itching was relatively high ($I^2 = 62\%$ and 92%, respectively), which may be related to the inconsistency of the nasal symptom score scale used by Xu et al. (32). Further sensitivity analysis was performed by eliminating this article with respect to nasal itching, and the results revealed that the heterogeneity was only 8% (Figure 9; MD = -0.45, 95% CI = -0.61 to -0.29, *P* < 0.01).

Total nasal symptom evaluation

Scores for total nasal symptoms were reported in 5 studies involving 150 children treated with pediatric tuina and 150 controls. The meta-analysis revealed that pediatric tuina was superior to other therapies in improving nasal symptoms (MD = -1.86, 95% CI = -2.76 to -0.95, P < 0.01). The heterogeneity of the included studies was relatively high ($I^2 =$ 75%), so a random-effects model was used. The results of the subgroup analysis showed that compared with the control group, pediatric tuina alone (MD = -2.32, 95% CI = -3.59 to -1.05, P < 0.01) or combined with other therapies (MD = -1.55, 95% CI = -2.73 to -0.36, P < 0.01) exhibited better overall symptom score and improvement (**Figure 10**).

Nasal sign evaluation

Three studies rated turbinate swelling and four rated nasal mucosal swelling. The results of these studies revealed that pediatric tuina was superior to the control group in improving turbinate swelling (Figure 11; MD = -0.26, 95% CI = -0.48 to -0.04, P < 0.01), with low heterogeneity $I^2 = 0\%$. However, compared with the control group, pediatric tuina exhibited no significant advantage in improving nasal mucosal swelling (Figure 12; MD = -0.17, 95% CI = -0.36 to 0.02, P = 0.07).

Publication bias

As the number of included RCTs was >10, a funnel plot was used to analyze the risk of publication bias. The result showed that the included studies were concentrated in the middle and top of the graph and the left–right distribution was basically symmetric, suggesting that the included studies had low publication bias (Figure 13).

	Experime	ental	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
1.1.1 pediatric tuina	VS other th	erapy					
Jiena Fu 2015	13	20	10	20	3.8%	1.30 [0.75, 2.24]	
Lingge Jiang 2017	28	30	26	30	9.8%	1.08 [0.91, 1.28]	
QI Sun 2018	27	30	24	30	9.1%	1.13 [0.91, 1.39]	
Qi Sun 2019	29	30	27	30	10.2%	1.07 [0.94, 1.23]	
Wengin Dai 2020	26	28	22	28	8.3%	1.18 [0.95, 1.47]	
Subtotal (95% CI)		138		138	41.1%	1.13 [1.02, 1.25]	◆
Total events	123		109				
Heterogeneity: Chi ² =	1.23, df = 4	(P = 0.)	87); I ² = (0%			
Test for overall effect:	Z= 2.39 (F	= 0.02)				
1.1.2 pediatric tuina	+ other the	rapy VS	s other th	егару			
Huixian Xu 2018	28	30	18	30	6.8%	1.56 [1.14, 2.12]	
Shu Chen 2016	28	30	28	30	10.6%	1.00 [0.87, 1.14]	
Tong Mou 2014	29	30	25	30	9.4%	1.16 [0.98, 1.38]	
Xia Liu 2014	18	30	11	30	4.2%	1.64 [0.94, 2.85]	
Xinglian Xu 2009	36	40	36	40	13.6%	1.00 [0.86, 1.16]	
Yating Fan 2019	27	40	23	40	8.7%	1.17 [0.83, 1.65]	
Zhiyong Shen 2015	19	20	15	20	5.7%	1.27 [0.96, 1.66]	
Subtotal (95% CI)		220		220	58.9%	1.19 [1.08, 1.31]	•
Total events	185		156				
Heterogeneity: Chi ² =	15.92, df=	6 (P = 1	0.01); I ^z =	62%			
Test for overall effect:	Z= 3.48 (F	= 0.00	05)				
Total (95% CI)		358		358	100.0%	1.16 [1.08, 1.25]	•
Total events	308		265				
Heterogeneity: Chi ² =	16.46, df=	11 (P =	0.13); I ^z	= 33%		7	
Test for overall effect:	Z=4.22 (F	< 0.00	01)				U.5 U.7 1 1.5 2 Favours [control] Favours [experimental]
Test for subaroup dif	ferences: C	hi ² = 0.9	50. df = 1	(P = 0.	48). I ² = 0	%	r avours [control] r avours [experimental]
E 4							

Mean Difference Experimental Control **Mean Difference** Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% Cl IV, Random, 95% CI 1.2.1 pediatric tuina VS other therapy Lingge Jiang 2017 1.1 0.31 30 1.8 0.85 30 19.2% -0.70 [-1.02, -0.38] QI Sun 2018 1.132 0.571 30 1.476 0.629 30 19.9% -0.34 [-0.65, -0.04] Qi Sun 2019 0.92 0.78 30 1.23 0.86 30 16.0% -0.31 [-0.73, 0.11] Subtotal (95% CI) 90 90 55.1% -0.46 [-0.71, -0.21] Heterogeneity: Tau² = 0.02; Chi² = 3.17, df = 2 (P = 0.21); I² = 37% Test for overall effect: Z = 3.64 (P = 0.0003) 1.2.2 pediatric tuina + other therapy VS other therapy Tong Mou 2014 0.9 0.92 30 0.8 0.88 30 14.7% 0.10 [-0.36, 0.56] Xinglian Xu 2009 2.18 1.5 40 3.3 1.31 40 10.6% -1.12 [-1.74, -0.50] Zhiyong Shen 2015 1.2 0.523 20 1.65 0.489 20 19.6% -0.45 [-0.76, -0.14] Subtotal (95% CI) 90 90 44.9% -0.46 [-1.04, 0.12] Heterogeneity: Tau² = 0.21; Chi² = 9.95, df = 2 (P = 0.007); l² = 80% Test for overall effect: Z = 1.54 (P = 0.12) Total (95% CI) 180 180 100.0% -0.44 [-0.70, -0.19] Heterogeneity: Tau² = 0.06; Chi² = 13.30, df = 5 (P = 0.02); l² = 62% -2 -1 Ó ż Test for overall effect: Z = 3.41 (P = 0.0007) Favours [experimental] Favours [control] Test for subaroup differences: Chi² = 0.00. df = 1 (P = 0.99). I² = 0% FIGURE 5 Forest plot for the treatment of nasal congestion symptom.

Discussion

The present meta-analysis included 12 published RCTs, 50% of which were published in the last 5 years. A previously

published systematic review (37) provided some suggestive evidence that pediatric tuina may be beneficial in the treatment of AR in children. However, this systematic review primarily included Chinese databases and two English





databases, excluding foreign language databases. Moreover, nearly 5 years have passed since its publication, and some follow-up latest clinical trials have not yet been analyzed. Compared with the previous meta-analyses, eight recent RCTs were included in the present analysis after an extensive search of Chinese, English, Korean, and Japanese databases. Pediatric tuina was considered the standard or adjunctive treatment for AR in children in all these trials. All 12 articles included in the study used the total effective rate as the outcome indicator, and the results revealed that compared with other therapies, pediatric tuina was more effective in treating children with AR. For the unsatisfactory effect of single medication, Allergic Rhinitis and its Impact on Asthma guidelines recommend the use of a combination regimen to treat children with AR (9). Current studies revealed that pediatric tuina combined with Western medicine, acupuncture, and traditional Chinese medicine was superior to a monotherapy in the treatment of pediatric systemic diseases (38–40). Consistent with the results of these studies, the present study confirmed that pediatric tuina combined with traditional Chinese herbal medicine was more effective in AR treatment.

The score of nasal symptoms and signs represents the severity of AR and is the most commonly used outcome evaluation indicator for AR (41). The subgroup analyses in the current study provided some confirmation that pediatric





tuina as a physiotherapy is superior to drugs or acupuncture in the relief of nasal symptoms scores such as nasal congestion, nasal itching, sneezing, runny nose, and turbinate swelling in pediatric patients with AR. Pediatric tuina for children with AR is based on the principle of combining local and remote acupoint selection and characterized by the local manipulation of the nose. The literature included in this study all implemented pediatric tuina on common nasal acupoints (such as Yingxiang, Bitong, Yintang, and others) to improve nasal redness, hot flashes, and local qi and blood circulation. Lei et al. also confirmed that the pediatric tuina of Bitong and Yingxiang significantly improved the nasal symptoms of children with AR (42). The included literature applied distal acupoint selection to treat children with AR, particularly the special acupoints below the elbows and knees of the limbs, including the lung meridian and spleen meridian (29, 30). By pushing and rubbing these acupoints, nasal allergy symptoms and immunity can be improved (43). The analysis showed that there is a high degree of heterogeneity in the improvement of nasal symptoms and signs with tuina. This may be attributed to inconsistencies in the rating scales used. In addition, different manipulation schemes (such as the





selected acupoints as well as the time and frequency of manipulation) are another source of high heterogeneity.

Among the 12 articles included in this study, only 3 articles reported adverse reactions. The analysis showed that there were no significant adverse reactions during the treatment of AR with pediatric tuina. Therefore, a meta-analysis of adverse reactions was not performed. Clinically, the most common adverse reaction of pediatric tuina is skin damage, which is mostly caused by improper manipulation. Skin damage can be avoided by adjusting different manipulation strengths according to the child's body constitution.

Despite the finding that pediatric tuina has significant clinical benefits in AR, the underlying mechanisms of its therapeutic action remain largely unexplored. Pediatric tuina and acupuncture therapy are guided by the basic principles of TCM using the theory of meridians and acupoints as the core. The clinical location of acupoints in the treatment of AR in children is roughly the same. The pediatric tuina treatment of AR employs fingers instead of acupuncture needles to manipulate meridian acupoints and trigger meridian conduction. Thus, pediatric tuna may have a similar mechanism of action to acupuncture in the treatment of AR, i.e., the stimulation of acupuncture points could activate the autonomic nervous system (44), trigger neural reflexes in the immune system, and decrease inflammatory cytokine and IgE levels (45, 46).

The efficacy of pediatric tuina has a certain correlation with age and intervention courses. The publication age of papers included in the present analysis ranged from 1 to 18 years. According to the Chinese Medical Encyclopedia, pediatric tuina is suitable for children aged <6 years, particularly for infants aged <3 years. However, optimal efficacy is based on the clinical experience of pediatric tuina experts. At present, there is still a lack of studies on the efficacy of pediatric tuina in different age groups, and additional clinical evaluations are needed in the future.

The present meta-analysis study has some limitations. First, there were multiple heterogeneities among the included trials regarding the type of AR, basic treatment (e.g., pharmacotherapy, traditional Chinese medicine, and acupuncture), scoring of nasal





symptoms, and variations in pediatric tuina procedures. Additional studies are needed to fully assess how these factors play a role in heterogeneity. Second, because the interventions of pediatric tuina were completely different from those of the control group, a relatively high risk of bias existed owing to the lack of blinding.

Conclusion

The present study revealed that pediatric tuina is a safe and effective treatment for AR in children as it can effectively relieve the nasal symptoms of children. Thus, pediatric tuina is worth promoting in clinical practice. Considering the small sample size and lack of follow-up data of the included studies, more multicentric RCTs with a large sample and sufficient follow-up duration are needed to validate these findings.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Author contributions

WYG (Corresponding author) conceived, designed and revised this study. LMC (Corresponding author) directed and revised the manuscript. FSF (Co-first author) was responsible for the performance of the research and literature retrieval. LYT (Co-first author) performed data extraction, chart making and writing of the paper. LRR performed extracted the data. RFJ participated in data analysis. PYJ helped to perform the literature retrieval. All authors contributed to the final manuscript. All authors approved the final version of the article, including the authorship list. All authors contributed to the article and approved the submitted version.

References

1. Bousquet J, Anto JM, Bachert C, Baiardini I, Bosnic-Anticevich S, Walter Canonica G, et al. Allergic rhinitis. *Nat Rev Dis Primers*. (2020) 6:95-111. doi: 10.1038/s41572-020-00227-0

2. Okubo K, Kurono Y, Ichimura K, Enomoto T, Okamoto Y, Kawauchi H, et al. Japanese Guidelines for allergic rhinitis 2020. *Allergol Int.* (2020) 69:331–45. doi: 10.1016/j.alit.2020.04.001

3. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: iSAAC phases one and three repeat multicountry cross-sectional surveys. *Lancet.* (2006) 368:733–43. doi: 10.1016/S0140-6736(06)69283-0

4. Cingi C, Muluk N B, Scadding G K. Will every child have allergic rhinitis soon? Int J Pediatr Otorhinolaryngol. (2019) 118:53–8. doi: 10.1016/j.ijporl.2018.12.019

5. Schuler CF, Montejo JM. Allergic rhinitis in children and adolescents. *Pediatr Clin North Am.* (2019) 66:981–93. doi: 10.1016/j.pcl.2019.06.004

6. Mariño-Sánchez F, Valls-Mateus M, Gonzalo DLS, Plaza AM, Cobeta I, Mullol J. Multimorbidities of pediatric allergic rhinitis. *Curr Allergy Asthma Rep.* (2019) 19:13–23. doi: 10.1007/s11882-019-0843-9

7. Cibella F, Ferrante G, Cuttitta G, Bucchieri S, Melis MR, La Grutta S, et al. The burden of rhinitis and rhinoconjunctivitis in adolescents. *Allergy Asthma Immunol Res.* (2015) 7:44–50. doi: 10.4168/aair.2015.7.1.44

8. Barr JG, Al-Reefy H, Fox AT, Hopkins C. Allergic rhinitis in children. *Br Med J.* (2014) 349:1–8. doi: 10.1136/bmj.g4153

9. Zhang L, Zhang Y, Zidarn M, Zuberbier T, Schünemann HJ. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. (2017) 140:950-8. doi: 10.1016/j.jaci.2017.09.009

10. Scadding GK, Kariyawasam HH, Scadding G, Mirakian R, Buckley RJ, Dixon T, et al. BSACI Guideline for the diagnosis and management of allergic and nonallergic rhinitis (revised edition 2017; first edition 2007). *Clin Exp Allergy.* (2017) 47:856–89. doi: 10.1111/cea.12953

11. Baroody FM, Naclerio RM. Antiallergic effects of H1-receptor antagonists. *Allergy.* (2000) 55(Suppl 64):17–27. doi: 10.1034/j.1398-9995.2000.00803.x

Funding

This study was financially supported by the grant of National Natural Science Foundation of China (Grant No: 81574091 and 81072892).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

12. Fireman P. Therapeutic approaches to allergic rhinitis: treating the child. J Allergy Clin Immunol. (2000) 105:S616–21. doi: 10.1067/mai.2000.106152

13. Italia S, Wolfenstetter SB, Teuner CM. Patterns of complementary and alternative medicine (CAM) use in children: a systematic review. *Eur J Pediatr.* (2014) 173:1413–28. doi: 10.1007/s00431-014-2300-z

14. Barreto DM, Batista M. Swedish Massage: a systematic review of its physical and psychological benefits. *Adv Mind Body Med.* (2017) 31:16–20. PMID: 28659510

15. Lu TY, Yin LJ, Chen RQ, Zhang H, Cai J, Li M, et al. Chinese Pediatric tuina on children with acute diarrhea: a randomized sham-controlled trial. *Health Qual Life Outcomes*. (2021) 19:4–14. doi: 10.1186/s12955-020-01636-1

16. Liang SB, Lai BY, Cao HJ, Cai QH, Bai X, Li J, et al. Pediatric tuina for the treatment of anorexia in children under 14 years: a systematic review and meta-analysis of randomized controlled trials. *Complement Ther Med.* (2020) 51:1–28. doi: 10.1016/j. ctim.2020.102411

17. Vickers A, Ohlsson A, Lacy JB, Horsley A Massage for promoting growth and development of preterm and/or low birth-weight infants (cochrane review). *Cochrane Database of Syst Rev (Online)*. (2004) 2:CD000390. doi: 10.1002/ 14651858.CD000390

18. Groenewald CB, Beals-Erickson SE, Ralston-Wilson J, Rabbitts JA, Palermo TM. Complementary and alternative medicine use by children with pain in the United States. *Acad Pediatr.* (2017) 17:785–93. doi: 10.1016/j.acap.2017.02.008

19. Ciccarelli M, Fraser K, Vaz S. Allied health management of technologyrelated musculoskeletal complaints among children and adolescents. *Aust Occup Ther J.* (2016) 63:399-407. doi: 10.1111/1440-1630.12320

20. Wolpert M, Dalzell K, Ullman R, Garland L, Cortina M, Hayes D, et al. Strategies not accompanied by a mental health professional to address anxiety and depression in children and young people: a scoping review of range and a systematic review of effectiveness. *The Lancet Psychiatry.* (2019) 6:46–60. doi: 10.1016/S2215-0366(18)30465-6

21. Ostojic K, Paget S, Kyriagis M, Morrow A Acute and chronic pain in children and adolescents with cerebral palsy: prevalence, interference, and

management. Arch Phys Med Rehabil. (2019) 101:213-9. doi: 10.1016/j.apmr.2019. 08.475

22. Juan RM, Blanca GS, Silvia TP, Martín JG, Jiménez-Palomares M, Bellino MN. Effects of the application of therapeutic massage in children with cancer: a systematic review. *Rev Lat Am Enfermagem.* (2017) 25:1–9. doi: 10.1590/1518-8345.1774.2903

23. Ji W, Yang XW, Ming Z. Massage therapy in children with asthma: a systematic review and meta-analysis. *Evid-based Complement Altern Med.* (2017):562–8. doi: 10.1155/2017/5620568

24. Fattah MA, Hamdy B. Pulmonary functions of children with asthma improve following massage therapy. J Altern Complement Med. (2011) 17:1065–8. doi: 10.1089/acm.2010.0758

25. Sun Q, Li ZX, Jing LJ, Shao Y. Effect of nine-method nasal massage on allergic rhinitis in children. *Guangdong Med J.* (2018) 39:1741-4. doi: 10.13820/j.cnki.gdyx.20180622.020

26. Dai WQ, Jin L, Dai SC, Yuan Q, Luo J. Clinical study on the treatment of pediatric allergic rhinitis by pediatric tuina based on the theory of "cultivating earth to produce gold". *Chinese Baby.* (2020) 8:94.

27. Jiang LG. Observation clinical curative effect of nasal eight methods of pediatric massage to lung qi deficiency type cold of pediatric allergic rhinitis. Guangzhou: Guangzhou University of Chinese Medicine. (2017).

28. Sun Q. Clinical observation of innovative method for rhinitis in children with allergic rhinitis. Guangzhou: Guangzhou University of Chinese Medicine. (2019).

29. Fu JN, Zhang WD, Li H. 20 Cases of pediatric chronic rhinitis treated with acupuncture combined with tuina. *Traditional Chinese Medicinal Research*. (2015) 28:52–3. doi: 10.3969/j.issn.1001-6910.2015.08.25

30. Xu HX, Shen ZY, Chen S, Shao AL. Clinical study of tuina combined with Chinese medicine for allergic rhinitis in children. *J Chin Med.* (2018) 50:135–8. doi: 10.13457/j.cnki.jncm.2018.03.036

31. Chen S. The clinical study of the bi-qiu massage treatment to effect children with allergic rhinitis. Guangzhou: Guangzhou University of Chinese Medicine. (2016).

32. Xu XL. Clinical study on qufengxuanqiao and qingfeihuatan decoction in the treatment of childhood allergic rhinitis. Nanjing: Nanjing University Of Chinese Medicine. (2009).

33. Shen ZY. The preliminary clinical study of the bi-qiu massage technique and Chinese herbals to cure children with allergic rhinitis. Guangzhou: Guangzhou University of Chinese Medicine. (2015).

34. Liu X. Acupoint massage combined with traditional Chinese medicine to treat allergic rhinitis in children of 30 cases. *Henan Tradit Chin Med.* (2014) 34:705–6. doi: 10.16367/j.issn.1003-5028.2014.04.058

35. Fan YT, Wang YH, Shao L. Clinical observation on relieving the symptoms of allergic rhinitis nasal congestion in children by combining double hundred granules with snap injection. *Guangming J Chin Med.* (2019) 34:547–9. doi: 10. 3969/j.issn.1003-8914.2019.04.021

36. Mou T. The clinical observation of infantile massage combined with Chinese patent medicine treating 60 cases of children allergic rhinitis with lung spleen qi deficiency syndrome. Guangzhou: Changchun University of Chinese Medicine. (2014).

37. Shi YJ, Zhao J, Zhao Y, Ren FJ, Wang YG. Systematic evaluation on clinical curative effects of tuina for allergic rhinitis in children. *Liaoning J Trad Chin Med.* (2018) 45:229–32. doi: 10.13192/j.issn.1000-1719.2018.02.002

38. Chen LL, Su YC, Su CH, Lin HC, Kou HW. Acupressure and meridian massage: combined effects on increasing body weight in premature infants. *J Clin Nurs.* (2010) 17:1174–81. doi: 10.1111/j.1365-2702.2007.02147.x

39. Gao L, Jia C, Huang H. Paediatric massage for treatment of acute diarrhoea in children: a meta-analysis. *BMC Complement Altern Med.* (2018) 18:257–67. doi: 10.1186/s12906-018-2324-4

40. Yang Y, Geng L, Cai J, Wang Y, Ping J. Clinical effect of rougan tongdu combined with point-pressing massage therapy on children at high risk of delayed motor development. *Ann Palliat Med.* (2020) 9:1174–9. doi: 10.21037/apm-20-1057

41. Storms WW, Segall N, Mansfield LE, Amar NJ, Kelley L, Ding Y, et al. Efficacy and safety of beclomethasone dipropionate nasal aerosol in pediatric patients with seasonal allergic rhinitis. *Ann Allergy Asthma Immunol.* (2013) 111:408–14. doi: 10.1016/j.anai.2013.07.033

42. Lei RL, Lin WC, Lin CC, Lei RW. Effects of acupressure on symptoms relief and improving sleep quality in pediatric patients with allergic rhinitis. *Holist Nurs Pract.* (2022) 36:166–74. doi: 10.1097/HNP.000000000000377

43. Yang S, Chen H, Lin Y, Chen Y. The exploration of disease pattern, zheng, for differentiation of allergic rhinitis in traditional Chinese medicine practice. *Evid-based Complement Altern Med.* (2012):1–7. doi: 10.1155/2012/521780

44. Mcdonald JL, Cripps AW, Smith PK. Mediators, receptors, and signalling pathways in the anti-inflammatory and antihyperalgesic effects of acupuncture. *Evid-based Complement Altern Med.* (2015) 2:1–10. doi: 10.1155/2015/975632

45. Mi J, Chen X, Lin X, Guo J, Chen H, Wei L, et al. Treatment of persistent allergic rhinitis via acupuncture at the sphenopalatine acupoint: a randomized controlled trial. *Trials.* (2018) 19:28–37. doi: 10.1186/s13063-017-2339-z

46. Mcdonald JL, Smith PK, Smith CA, Changli Xue C, Golianu B, Cripps AW, et al. Effect of acupuncture on house dust mite specific IgE, substance P, and symptoms in persistent allergic rhinitis. *Ann Allergy Asthma Immunol.* (2016) 116:497–505. doi: 10.1016/j.anai.2016.04.002